Peptide Dosage Protocols: What Studies Used

Peptide dosage is one of the most searched and most misunderstood topics in the research peptide space. Forums and vendor pages routinely list specific microgram amounts as if they were established human protocols. They are not. What exists in the published literature is a collection of animal study doses, primarily from rat experiments, that tell us what researchers used in controlled settings. We compiled the actual study data below. The most common figure is 10 mcg/kg body weight administered intraperitoneally in rats for BPC-157. That number describes an animal research protocol. It does not transfer to humans.

What Published Studies Actually Used

BPC-157 Dosing in Rat Models

Across more than 40 preclinical papers, BPC-157 was most frequently administered at 10 mcg/kg body weight via intraperitoneal (IP) injection. Some studies also tested 10 ng/kg (a thousand-fold lower dose) and found comparable effects, suggesting a flat dose-response curve in certain models. The Zagreb group used daily dosing for periods ranging from 7 to 28 days depending on the injury model. Oral (intragastric) administration was tested in gut-specific studies and produced comparable outcomes for gastrointestinal endpoints.

TB-500 Dosing in Animal Models

Thymosin Beta-4 studies used different dosing conventions than BPC-157 research. Rather than weight-based microgram-per-kilogram dosing, several TB-4 studies administered fixed total amounts per animal. For example, a 2004 cardiac repair study by Bock-Marquette et al. gave 150 mcg total IP to mice after coronary ligation. Wound healing studies used topical application at 5 mcg per wound site. We found that direct comparison between BPC-157 and TB-500 dosing is complicated by these different conventions.

Why Allometric Scaling Does Not Give You a Human Dose

What the FDA Guidance Actually Says

The FDA published a guidance document on estimating maximum safe starting doses for initial clinical trials in healthy adult volunteers. This document describes a body surface area (BSA) scaling method that uses species-specific conversion factors. For rat to human, the factor is 6.2: you divide the rat dose (in mg/kg) by 6.2 to get the human equivalent dose (HED) in mg/kg.

Here is the critical part that forums and vendor pages consistently omit. The FDA guidance states explicitly that the HED is a starting point for Phase I safety trials. It is the maximum safe starting dose for the first time a compound enters humans in a controlled clinical setting with medical monitoring. It is not a therapeutic dose. It is not an efficacy dose. It is the dose at which a Phase I trial would begin, and it would then be escalated under medical supervision with safety monitoring at each step.

A Worked Example (Arithmetic, Not Advice)

If the most common rat BPC-157 dose is 10 mcg/kg IP, the naive HED calculation would be 10 / 6.2 = 1.6 mcg/kg for a human. For a 70 kg person, that gives 112 mcg total. This number appears on many forums as if it were a validated dose. It is not. The calculation ignores species differences in receptor density, metabolic clearance, bioavailability by different routes, protein binding and volume of distribution. We present it only to show the math that others reference and to explain why it falls short.

Species Differences That Break the Conversion

Rats are not small humans. Their metabolic rate per kilogram of body weight is approximately 7 times higher than that of humans. Their gastrointestinal transit time, hepatic first-pass metabolism and renal clearance rates all differ substantially. BPC-157 has been tested primarily via intraperitoneal injection in rats. Humans do not use the IP route clinically. Subcutaneous injection, which is the route most commonly discussed in online communities, was not the primary route in the published studies. Changing the route changes the pharmacokinetics. The only published human data (Lee and Burgess 2025) used intravenous administration at doses up to 20 mg total, which is roughly 285 mcg/kg for a 70 kg subject, far above the naive HED calculation.

Reconstitution Math for Research Use

Standard Reconstitution Procedure

Lyophilized peptide vials are reconstituted by adding bacteriostatic water (0.9% benzyl alcohol) slowly along the inside wall of the vial. The powder should dissolve without shaking. Common bacteriostatic water volumes are 1 mL or 2 mL per vial. Real Peptides sells bacteriostatic water at $4.80 for a 10 mL vial. After reconstitution, the solution should be refrigerated and used within 28 days.

Concentration Calculation

Concentration (mcg/mL) = total peptide in vial (mcg) / volume of water added (mL). For a 5 mg (5000 mcg) vial reconstituted with 2 mL of water: 5000 / 2 = 2500 mcg/mL. Each 0.1 mL (10 units on a U-100 insulin syringe) would contain 250 mcg. For a 10 mg vial with 2 mL: 10000 / 2 = 5000 mcg/mL, and 0.1 mL = 500 mcg.

Route of Administration in Published Studies

Intraperitoneal (IP)

The vast majority of BPC-157 studies used IP injection. This route delivers the peptide directly into the peritoneal cavity, where it is absorbed through the peritoneal membrane into systemic circulation. IP injection is standard in rodent research but is not used clinically in humans. The pharmacokinetics of IP administration do not translate directly to subcutaneous or intramuscular routes.

Oral and Intragastric

BPC-157's acid stability allows oral administration in rats. For gut-specific endpoints (gastric ulcer protection, colitis models), oral BPC-157 produced results comparable to IP injection. For systemic endpoints (tendon, muscle), oral bioavailability and distribution are less well characterized. Whether oral BPC-157 reaches distant tissues at effective concentrations in any species is an open question.

Subcutaneous and Topical

Some studies tested local subcutaneous injection near the injury site or topical application as a cream. Both showed trends toward positive outcomes. These routes are more relevant to how human communities discuss use, but the published data using these routes is smaller than the IP dataset. For the BPC-157 peptide therapy landscape, see our BPC-157 peptide therapy guide.